erythropoiesis-stimulating agent

(redirected from Erythropoiesis stimulating agent)
Also found in: Wikipedia.

erythropoiesis-stimulating agent

Abbreviation: ESA.
Any drug that binds to cellular receptors for erythropoietin and encourages red blood cell production by the bone marrow. Members of this class of drugs, which include epoietin and darbopoietin, are used to treat anemia, e.g., in patients with chronic kidney disease, cancer, or aplastic anemia. ESAs are used as an alternative to red blood cell transfusions. Potential side effects of treatment include high blood pressure and an increased risk of blood clots.
See also: agent
References in periodicals archive ?
Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No.
Tokyo, Japan, Apr 25, 2007 - (JCN) - Kirin Brewery announced that it received manufacturing and marketing approval for its long-acting erythropoiesis stimulating agent Darbepoetin Alfa, brand name NESP(R) Injection Syringe, on April 18, 2007.
Peginesatide is a synthetic PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA).
Hematide, a peptide-based erythropoiesis stimulating agent (ESA) being developed by Affymax, is currently in clinical trials for the treatment of anemia associated with chronic kidney disease, cancer and other diseases.
If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent (ESA) available for the treatment of anemia associated with CKD patients on dialysis in the United States.
Over 80 percent of surveyed nephrologists were aware that Affymax/Takeda Pharmaceuticals' Omontys - an erythropoiesis stimulating agent (ESA) - was voluntarily recalled in February 2013 due to new postmarketing reports regarding serious hypersensitivity reactions.
Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp(R) (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No.
Hematide is a novel synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA).
Preliminary data from the Phase 2 randomized, active-controlled, open-label trial were presented in a poster entitled "Preliminary Analysis of Once-Monthly Hematide Efficacy and Safety in Hemodialysis Patients not on erythropoiesis stimulating agent (ESA) Treatment.
These include preliminary results of a Phase 2 trial in hemodialysis (HD) patients who are not on an erythropoiesis stimulating agent (ESA), and interim results from an ongoing Phase 2 study in patients with antibody-mediated pure red cell aplasia (Ab+PRCA).
Woodburn also presented a poster (Abstract #1155) entitled "Chronic Preclinical Safety Evaluation of Hematide, a PEGylated Peptidic Erythropoiesis Stimulating Agent, in Monkeys.
Other key findings from the report entitled Treatment Algorithms in Nephrology: An Analysis of Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney Disease and Phosphate Binders in Dialysis :